News in English
The difficulty of securing capital for life science development companies in recent years has hardly gone unnoticed. The question is whether this financial permafrost is the result of a series of unfortunate, interacting circumstances, or whether it is a natural development in an industry where the willingness to pay for incremental improvements is weakening?
Anna Törner: ”Drug prices – an important driver of innovation”
We live under the illusion that no price is too high when it comes to health, but that simply isn’t true, writes Anna Törner.
Annons
BREAKING